Inclusion Criteria:

- Written informed consent

- Age > 18

- Histological diagnosis of non small-cell lung cancer (NSCLC)

- Stage IIIb or Stage IV disease (in IIIb, previous treatment with chemotherapy +
radiotherapy, or metastatic supraclavicular lymph nodes or pleural effusion)

- Disease in progression

- Previous chemotherapy with platinum-derivative (and with > 21 days from last
administration)

Exclusion Criteria:

- ECOG performance status > 2

- Age > 75 years

- History of malignant neoplasm within the previous 5 years (except for baso- or
spino-cellular skin carcinoma and in-situ carcinoma of the uterine cervix, provided
they are being adequately treated)

- Previous treatment with docetaxel

- Presence of symptomatic cerebral metastasis

- Neutrophils < 2.0 x 109/l, platelets < 100,000/l, hemoglobin > 10g/dl

- Bilirubin < 1.5 x the upper normal limit

- SGOT , SGPT, or bilirubin > 1.25 x the upper normal limits except in the presence of
hepatic metastasis

- Creatinine >1.25 x the upper normal limit

- Any concomitant pathology that would, in the Investigator's opinion, contraindicate
the use of the drugs in the protocol

- Inability to comply with follow up

- Pregnant or nursing females